Comparative Pharmacology
Head-to-head clinical analysis: AMNESTROGEN versus DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTROGEN versus DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM.
AMNESTROGEN vs DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
None Documented
None Documented
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Category C
Category D/X
Estrogen
Progestin + Estrogen